Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker Corporation has released its earnings for the second quarter of 2024, showing a robust performance marked by a strong organic growth sales of 9% year-over-year.</li><li>The diversified medical technology company's balanced growth across its MedSurg and Neurotechnology and Orthopaedics and Spine segments underpins its broad performance and robust demand for its products.</li><li>The global organic growth was evenly distributed with both U.S. and international markets expanding by approximately 9%.</li></ul>

Stryker Corporation has released its earnings for the second quarter of 2024, showing a robust performance marked by a strong organic growth sales of 9% year-over-year.The diversified medical technology company's balanced growth across its MedSurg and Neurotechnology and Orthopaedics and Spine segments underpins its broad performance and robust demand for its products.The global organic growth was evenly distributed with both U.S. and international markets expanding by approximately 9%.

Stryker Corporation: The Artelon Acquisition

<ul><li>Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and capital, strong pipeline production, and the easing of macro constraints.</li><li>The company exceeded $20 billion in sales, marking another high-growth year, and reported over 11% sales growth in Q4 and for the full year.</li><li>Margin recovery continued as well, with a 13% compared to the full year of 2022, due to strong sales.</li></ul>

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and capital, strong pipeline production, and the easing of macro constraints.The company exceeded $20 billion in sales, marking another high-growth year, and reported over 11% sales growth in Q4 and for the full year.Margin recovery continued as well, with a 13% compared to the full year of 2022, due to strong sales.

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

<ul><li>Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at 9.2%.</li><li>Endoscopy also achieved a US organic sales growth of 10.6%, driven by communications and sustainability businesses, while Neurovascular and Neuro Cranial showcased solid performances.</li><li>Considering strong performance, a robust backlog for capital equipment, and positive procedure trends, Stryker's team expects full-year 2023 organic sales growth from 10% to 10.5%.</li></ul>

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at 9.2%.Endoscopy also achieved a US organic sales growth of 10.6%, driven by communications and sustainability businesses, while Neurovascular and Neuro Cranial showcased solid performances.Considering strong performance, a robust backlog for capital equipment, and positive procedure trends, Stryker's team expects full-year 2023 organic sales growth from 10% to 10.5%.

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

<ul><li>Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of 11.9%.</li><li>US and international organic sales demonstrated strong momentum despite a slight unfavorable impact from foreign currency exchange.</li><li>Lastly, the company expects organic sales growth for the entire year and adjusted EPS, highlighting its strong performance and positive outlook.</li></ul>

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of 11.9%.US and international organic sales demonstrated strong momentum despite a slight unfavorable impact from foreign currency exchange.Lastly, the company expects organic sales growth for the entire year and adjusted EPS, highlighting its strong performance and positive outlook.

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products. The Company's products include implants, biologics, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, communications and digital imaging systems, as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker (SYK UN)

Stryker Corporation: The Artelon Acquisition

Stryker Corporation has released its earnings for the second quarter of 2024, showing a robust performance marked by a strong organic growth sales...

Baptista Research

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and...

Baptista Research

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at...

Baptista Research

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Stryker Corporation: The Artelon Acquisition

Stryker Corporation has released its earnings for the second quarter of 2024, showing a robust performance marked by a strong organic growth sales...

Baptista Research

Stryker Corporation: Growing Adoption of Robotic Systems & Improving Ortho Market Outlook Are Green Signals! - Major Drivers

Stryker Corporation presented impressive financial results during their recent earnings call, driven by a robust demand for both procedures and...

Baptista Research

Stryker Corporation: How Strategic Acquisitions Propel Market Success! - Major Drivers

Stryker Corporation delivered a solid result and managed an all-around beat in the last quarter, experiencing robust organic sales growth at...

Baptista Research

Stryker Corporation: A Health Giant Flexing its Muscles in MedSurg and Neurotech! - Major Drivers

Stryker Corporation delivered a strong result and managed an all-around beat in the last quarter, marked by robust organic sales growth of...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...